Premium
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
Author(s) -
Ackerman Zvi,
OronHerman Mor,
Pappo Orit,
Peleg Edna,
Safadi Rifaat,
SchmilovitzWeiss Hemda,
Grozovski Maria
Publication year - 2010
Publication title -
basic and clinical pharmacology and toxicology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.805
H-Index - 90
eISSN - 1742-7843
pISSN - 1742-7835
DOI - 10.1111/j.1742-7843.2010.00553.x
Subject(s) - rosiglitazone , metabolic syndrome , medicine , pharmacology , endocrinology , diabetes mellitus
Rats given fructose‐enriched diet develop many characteristics of the human metabolic syndrome and non‐alcoholic fatty liver disease. In this study, we characterized the hepatic effects of rosiglitazone in fructose‐enriched diet rats. Rats were randomly divided into three groups. One group was maintained on standard rat chow diet for 6 weeks, whereas the other two groups were given fructose‐enriched diet for 6 weeks. Four weeks after the initiation of fructose‐enriched diet, one of the fructose‐enriched diet groups was also given rosiglitazone (10 mg/kg/day) for an additional 2 weeks. Rosiglitazone administration to the fructose‐enriched diet rats was associated with decreases in the following parameters: blood pressure (−17%), plasma triglycerides (−62%), hepatic total lipids (−19%), hepatic triglycerides (−61%), hepatic malondialdehyde (−88%), glutathione reductase activity (−84%). An increase in adiponectin plasma levels (+329%), hepatic phospholipids (+46%), hepatic α‐tocopherol concentrations (+24%) and hepatic paraoxonase activity (+68%) was observed. Rosiglitazone caused a decrease in hepatic macrovesicular steatosis score but no change in hepatic fibrosis. Administration of rosiglitazone, to rats with the metabolic syndrome has limited hepatic favourable effects: it improves hepatic lipid metabolism, decreases macrovesicular steatosis and improves some of the hepatic oxidative–anti‐oxidative milieu but has no effect on hepatic fibrosis.